Wainwright bullish on Seattle Genetics on tucatinib prospects, sees 34% upside - Seeking Alpha

Herald KS
Wainwright bullish on Seattle Genetics on tucatinib prospects, sees 34% upside
Seeking Alpha
Uber-bull H.C. Wainwright likes Seattle Genetics' (SGEN +8.7%) $614M takeout of Cascadian Therapeutics (BUY/$75). Analyst Andrew Fein says investors may not fully appreciate the value of Cascadian's lead drug tucatinib, a tyrosine kinase inhibitor that ...
Seattle Genetics' (SGEN) Buy Rating Reaffirmed at HC WainwrightStockNewsTimes
HC Wainwright Reiterates $75.0 Target Price On Seattle Geneti